Sensitive Mutation Detection Using TaqMan Liquid Biopsy dPCR Assays
Optimized solution for cancer research
Sensitive detection of low-frequency mutant alleles has extensive implications for cancer research. The accumulation of mutations in oncogenes or tumor suppressor genes is an important aspect of tumorigenesis. The TaqMan Digital PCR Liquid Biopsy assays, combined with the Oncomine cfDNA solutions, offer a comprehensive set of tools for liquid biopsy applications, and in the future may enable noninvasive techniques towards personalized medicine.
The TaqMan dPCR Liquid Biopsy Assays have been wet-lab tested and guaranteed to perform on the Applied Biosystems QuantStudio 3D and Bio-Rad* QX-100 and QX-200 systems. Download the quick reference guides on how to use TaqMan dPCR Liquid Biopsy Assays for QuantStudio 3D or Bio-Rad QX-100™ and QX-200™ systems* today.
Since these mutations are usually present only in a very small number of cells, they require an assay that delivers high signal-to-noise ratios and low false-positive rates.
By combining TaqMan fluorogenic 5’ nuclease chemistry with digital PCR methodology, researchers are now able to detect low-frequency mutations. Applied Biosystems TaqMan dPCR Liquid Biopsy assays for research have been optimized to work with digital PCR and droplet digital PCR systems to achieve the high performance required to detect and quantify mutations present at very low frequencies.
Our sensitive mutation detection solution includes a set of wet lab-verified TaqMan dPCR Liquid Biopsy assays for research to detect and quantify the most common cancer-related mutations (e.g., EGFR, BRAF, KRAS, PIK3CA, JAK2, and others). These assays, designed using the full bioinformatics power of the TaqMan Assay design pipeline, allow researchers to quantify rare mutants at a prevalence of ≤0.1% (Figure 1).
How to order TaqMan dPCR Liquid Biopsy assays
Tracking mutations in cfDNA and CTCs
Luca Quagliata, MD, University Hospital, Basel, Switzerland, talks about his research tracking mutations in metastatic prostate cancer samples using cfDNA and CTCs.
Looking at tumor evolution with cfDNA
Professor José Luis Costa, PhD, IPATIMUP, discusses use of cfDNA to detect rare mutations in lung cancer research blood samples.
Digital PCR for Rare Mutation Analysis
Discover the importance of detecting rare mutations in cancer research and learn how to use the QuantStudio 3D rare mutation analysis solution for sensitive detection of rare mutations.
Overview of sensitive mutation detection using TaqMan dPCR Liquid Biopsy assays
- Optimized digital PCR performance—wet lab–verified TaqMan assays targeting over 100 common cancer mutations
- High sensitivity—detect and quantify rare mutant prevalence to ≤0.1%
- Cost-effective and convenient—single-tube format includes both wild type and mutant alleles
- Streamlined analysis—advanced algorithms for better quantification of rare mutations
- Guaranteed performance—assay replaced or account credited if you are not satisfied
- Custom design support—guidance available for Custom TaqMan SNP Genotyping assays on the QuantStudio 3D Digital PCR System that are not part of this wet lab–verified collection
Poster: Orthogonal Verification of Oncomine cfDNA Data with Digital PCR Using TaqMan dPCR Liquid Biopsy Assays
Poster: TaqMan dPCR Liquid Biopsy Assays Targeting the TERT Promoter Region
Product Overview: QuantStudio 3D Digital PCR Solution for Rare Mutation Analysis
Product Bulletin: QuantStudio 3D Digital PCR System
Quick Reference Card: Rare Mutation Analysis Using the QuantStudio 3D Digital PCR System
Quick Reference Card: Mutation Detection Using the TaqMan dPCR Liquid Biopsy Assays on the Bio-Rad QX100/QX200 Systems
User Guide: QuantStudio 3D Digital PCR System
Digital PCR Experiment Design Guide
Multiplex TaqMan Assays for Rare Mutation Analysis Using Digital PCR
Fusion Transcript Detection with Digital PCR
For Research Use Only. Not for use in diagnostic procedures.